tbuckley/cabot-search huggingface dataset:
PTH-015 Developing The Recorded Image Quality Index (RIQI) Tool – Measuring Recorded Image Quality, Degree of Representation and Utility
Authors: D Samuel, JB Berrill, J Hurley, B Lee, E Hawkes, S Yosief, N Hawkes
Journal: Gut (2016)

<h3>Introduction</h3> Endoscopic images saved on the Electronic Reporting System are the only visible representation of completeness of examination and pathological findings. Together with the endoscopy report these become the only reference for other clinicians not present at the original endoscopy on which to base further decisions. Given the importance of these images, we aimed to develop a systematic scoring system for quality of images recorded at endoscopy and to validate this Recorded Image Quality Index (RIQI) scoring system <h3>Methods</h3> We searched the HICCS Endoscopic Reporting System for all colonoscopists performing regular colonoscopy (n = 11). All procedures performed between July and December 2015 were identified (screening cases were excluded). All images and the endoscopy report for the first 10 cases with pathological findings for each colonoscopist were obtained, ordered into folders and data anonymised. A RIQI scoresheet was devised assessing 4 domains (Representation (REP), Image Labelling (LAB), Caecal landmarks (CL) and Image Quality (QUAL)) and rating the utility (U) of the information set further decision-making. 110 image sets were scored by 3 independent assessors. Cohen’s kappa values for intra observer variation were calculated each domain. Correlation between domain and utility scores was calculated using Cohen’s kappa values for inter-rater agreement (IRA); these informed the score weighting in the final RIQI tool. <h3>Results</h3> 110 data sets were reviewed by 3 assessors generating 330 domain scores. IRA for assessors by domain was: REP 0.53, 0.53 &amp; 0.53 (moderate); LAB 0.82, 0.84 &amp; 0.73 (very good); CL 0.44, 0.49 &amp; 0.52 (moderate); QUAL 0.53, 0.39 &amp; 0.44 (moderate). Agreement for utility scores were 0.68, 0.42 and 0.36 (good-moderate). IRA was optimal using 3 point scales (c.f. 4 or 5 point domain rating scales). REP and QUAL domains closely correlated with utility scores (r = 0.68 &amp; 0.64) and were weighted accordingly in the final scoring system. Derived RIQI scores for each assessor correlated closely with clinical utility scores (r = 0.62, 0.63 &amp; 0.73). <h3>Conclusion</h3> The RIQI tool provides a method for assessing the quality of image capture across ten procedures with scores in 4 domains. The RIQI score correlates well with clinical utility of the images, with acceptable inter-rater reliability. It shows potential both as an audit and training tool to improve performance in this area of endoscopic practice. <h3>Disclosure of Interest</h3> None Declared
Mir-135a Expression Is Associated with Relapse in Hodgkin Lymphoma.
Authors: Alfons Navarro, Anna Gaya, Aina Pons, Alvaro Urbano-Ispizua, Antonio Martinez, Bernat Gel, Olga Balagué, Miquel Granell, Rosa Artells, Pau Abrisqueta, Armando Lopez-Guillermo, Emili Montserrat, Mariano Monzo
Journal: Blood (2007)
AB0794 Possible Molecular Mechanism of Lactoferrin Action on Bone Formation
Authors: P. Sadchikov, I. Goldman, A. Chernousov, E. Sadchikova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Lactoferrin (LF) is a multifunctional protein, for which several biological activities were determined, among which the main are antimicrobial, antiviral, antifungal, anti-inflammatory and antioxidant effects. LF takes an active part in stimulation of tissue regeneration processes. LF9s active role in the stimulation of tissue regeneration processes was established. In the last decade LF has also been shown to play the role in bone formation. <h3>Objectives</h3> In experiments carried out in different countries, it was found that the ovariectomized experimental animals, when giving LF per os, achieved relief of symptoms of osteoporosis, occurring at similar postmenstrual osteoporosis in women and human aging. Accumulating facts are showing a decrease in physiological serum LF in patients under pathological conditions of bone formation. In molecular genetic studies the identical mechanisms, resulting in reduced expression of LF and the emergence of bone desorption were determined. <h3>Methods</h3> We present a possible model of bone formation under the LF influence (Fig). <h3>Results</h3> According to our conception in osteoporosis, various injuries, or surgical impacts associated with the bones, the involvement of LF in the regenerative processes of the bone formation, apparently, is implemented as follows: as a result of damage of different tissues are released risk molecules – alarmins (high-mobility group protein B1 (HMGB1), S100 protein, IL-α, IL-33), which are necessary to repair damaged tissues, including bone. They interact with alarmins receptors on the surface of leukocytes, thus there is a release of proinflammatory cytokines (TNFα, IL-6, IL-1β, IL-8, INFγ) (Fig. Phase I). Further, under the action of IL-8, which is a chemotactic factor for neutrophils in the bone defect area segmented leukocytes migrate from granules which stands LF (Fig. Phase II). Then LF immerses in osteoblasts (OB), activating them, and osteoclasts (OC), inhibiting their activity (Fig. Phase III). <h3>Conclusions</h3> According to the presented model, the LF is simultaneously a factor of implementing the calcium transfer. The ability of LF to bind calcium is well known. The transfer of calcium in the bone tissue due to the complex LF-Calmodulin-Ca ++ (Fig.). It is possible that the expansion of research of the role of LF in bone formation will help create new and effective drugs to combat osteoporosis. <h3>Disclosure of Interest</h3> None declared
Lipid Emulsion as Antisense Oligonucleotides Vector That Inhibits P-Glycoprotein Expression in a Sarcoma Cell Line through LDL Receptor
Authors: Debora Levy, Adriana Aguiar Debes, Andrea Turbuck Celestino, Shirley Schreier, Raul Maranhão, Sergio Paulo Bydlowski
Journal: Blood (2008)
Trusts and CCG behind collapse of £800m contract were “grossly irresponsible,” say MPs
Authors: Gareth Iacobucci
Journal: BMJ (2016)

A landmark £800m (€930m; $1bn) contract to provide older people’s and adult community services collapsed just months into operation because of the “grossly irresponsible” actions of NHS commissioners and the service provider, an influential committee of MPs has concluded.

In a damning report,1 the House of Commons Public Accounts Committee said that services for patients would suffer as a result of the failed deal between Cambridgeshire and Peterborough Clinical Commissioning Group and UnitingCare Partnership, a partnership between Cambridge University Hospitals NHS Foundation Trust and Cambridgeshire and Peterborough NHS Foundation Trust.2

The deal, which was one of the largest outsourcing deals ever …
Rituximab-Mediated Inhibition of the Transcription Repressor Yin-Yang 1 (YY1) in NHL B Cell Lines: Upregulation of Fas Expression and Sensitization to Fas-Induced Apoptosis.
Authors: Mario I. Vega, Sara Huerta-Yepez, Ali R. Jazirehi, Hermes Garban, Benjamin Bonavida
Journal: Blood (2004)
Factor VIII Dosing and Preventive Efficacy in Obese Patients with Hemophilia (BMI ≥30 kg/m2) – a Post-Hoc Sub-Analysis of the guardian™ Trials
Authors: Michael Recht, Steven R. Lentz, Silva Zupancic-alek, Irina Matytsina, Andrea Landorph, Trine Saugstrup
Journal: Blood (2014)
RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,
Authors: Marlise R Luskin, Federico Campigotto, Paul G. Richardson, John Koreth, Irene M. Ghobrial, Robert Schlossman, Robert J Soiffer, Nikhil C. Munshi, Diane Warren, Muriel Gannon, Kathleen Finn, Kenneth C Anderson, Edie Weller, Jacob P. Laubach
Journal: Blood (2011)
Abstract 16113: Upregulation of Cardiac β3-Adrenergic Signaling Promotes Heart Failure Progression
Authors: Xiaowei Zhang, Tiankai Li, Heng-Jie Cheng, Peng Zhou, Michael Callahan, Che Ping Cheng
Journal: Circulation (2015)

Background. The negative inotrope and upregulation of β 3 -adrenergic receptors (AR) in failing human and animal hearts suggest a direct and contributing role of cardiac β 3 -AR activation on heart failure (HF) progression. However, its precise role is still being debated. We hypothesize that up-regulation of β 3 -AR is detrimental and chronic β 3 -AR blockade may limit or prevent the progression of HF. Methods. We determined Left ventricular (LV) and myocyte functional response and β 1 - and β 3 -AR expressions in 3 groups of rats (6/group) for a period of 4 months: 1) Isoproterenol (ISO)-treated, 4 months after receiving ISO (170 mg/kg, sq, for 2 days); 2) ISO/β 3 -ANT, two months after receiving ISO, L-748,337, a selective β 3 -AR antagonist (β 3 -ANT) (10 -7 M/kg/day by implanted osmotic mini pump) was initiated after established HF and was given for 2 months; and 3) sham controls. Results. Compared with controls, ISO-treated rats had HF onset at one month after ISO and progressed to severe HF at 4 months. Plasma norepinephrine (NE, 1482 vs 247 pg/ml) increased 6 fold. Both stroke volume (SV) and ejection fraction (EF, 32% vs 61%) decreased more than 48%, and LV end-diastolic pressure (P ED , 15.4 vs 6.0 mmHg) doubled, parallel with 48% reductions in cell contraction (dL/dt max, 78 vs 149 μm/s) and relaxation (dR/dt max , 66 vs 128 μm/s) and a much less increase in dL/dt max (30% vs 74%) in response to superfusion of ISO (10 -8 M). These changes were associated with significantly decreased β 1 -AR mRNA (0.30 vs 0.64) and protein levels (0.36 vs 0.62), but increased β 3 -AR mRNA (1.29 vs 0.52) and protein levels (0.35 vs 0.18). Treatment with β 3 -ANT significantly decreased P ED and plasma NE (191 pg/ml). Both SV and EF (59%) increased to more than 76% from ISO-treated values. The signal ratios of β 1 -AR mRNA (0.61) and β 3 -AR mRNA (0.59) remained close to control levels. ISO-induced increase in dL/dt max (75%) was also significantly augmented. Conclusion. Chronic β 3 -ANT prevented plasma norepinephrine elevations and causes normalization of β 1 - and β 3 -AR gene expression, restores normal responsiveness of myocyte to β-AR stimulation, and leads to regression of LV and myocyte dysfunction in a rat model of progressive HF. Thus, β 3 -AR blocker may provide a new therapeutic strategy for the treatment of HF.
Preliminary Phase II Results of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Cutaneous Anaplastic Large Cell Lymphoma (ALCL).
Authors: Madeleine Duvic, Joy Kunishige, Youn H. Kim, Andres Foreno-Torres, Lauren C. Pinter-Brown, Mark U. Rarick, John Zic, Sophie M. Worobec, Francine Foss, Karen Flessland, Jeremy Barton
Journal: Blood (2005)
Dermatological content of U.K. undergraduate curricula: where are we now?
Authors: A. Yaakub, S.N. Cohen, M. Singh, J.M.R. Goulding
Journal: British Journal of Dermatology (2016)

Given its impact, prevalence and especially its prominence in primary care 1, the importance of all medical graduates developing knowledge and awareness of skin disease ought to go without saying. Yet a previous audit of undergraduate teaching against the recommendations of the British Association of Dermatologists (BAD) identified important omissions in the courses of some medical schools 2. We recently undertook a survey of all medical schools in the UK and Ireland to investigate whether this had changed. The benchmark for course content derived from the BAD recommendations for undergraduates.

This article is protected by copyright. All rights reserved.
Effects of low alcohol consumption on pregnancy and childhood outcomes: a systematic review and meta-analysis
Authors: Loubaba Mamluk, Hannah B Edwards, Jelena Savović, Verity Leach, Timothy Jones, Theresa H M Moore, Sarah J Lewis, Jenny L Donovan, Deborah A Lawlor, George Davey Smith, Abigail Fraser, Luisa Zuccolo
Journal: The Lancet (2016)
Regeneration of CD8αβ T Cells from T-cell–Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity
Authors: Takuya Maeda, Seiji Nagano, Hiroshi Ichise, Keisuke Kataoka, Daisuke Yamada, Seishi Ogawa, Haruhiko Koseki, Toshio Kitawaki, Norimitsu Kadowaki, Akifumi Takaori-Kondo, Kyoko Masuda, Hiroshi Kawamoto
Journal: Cancer Research (2016)

Although adoptive transfer of cytotoxic T lymphocytes (CTL) offer a promising cancer therapeutic direction, the generation of antigen-specific CTL from patients has faced difficulty in efficient expansion in ex vivo culture. To resolve this issue, several groups have proposed that induced pluripotent stem cell technology be applied for the expansion of antigen-specific CTL, which retain expression of the same T-cell receptor as original CTL. However, in these previous studies, the regenerated CTL are mostly of the CD8αα+ innate type and have less antigen-specific cytotoxic activity than primary CTL. Here we report that, by stimulating purified iPSC-derived CD4/CD8 double-positive cells with anti-CD3 antibody, T cells expressing CD8αβ were generated and exhibited improved antigen-specific cytotoxicity compared with CD8αα+ CTL. Failure of CD8αβ T-cell production using the previous method was found to be due to killing of double-positive cells by the double-negative cells in the mixed cultures. We found that WT1 tumor antigen-specific CTL regenerated by this method prolonged the survival of mice bearing WT1-expressing leukemic cells. Implementation of our methods may offer a useful clinical tool. Cancer Res; 76(23); 6839-50. ©2016 AACR.
PTU-106 Improved Survival and Independance from Parental Nutrition for Patients with Intestinal Dysmotility
Authors: R Appleby, C Yu, J Nightingale
Journal: Gut (2016)

<h3>Introduction</h3> Patients receiving home parental nutrition (HPN) for intestinal dysmotility have a poor 5 years survival of 68% and independence from HPN at 5 years of 12% (<i>Lloyd et al. </i>2006<sup>1</sup>). Only abdominal malignancy patients fared worse. We aimed to compare the same outcomes, at the same centre 10 years since this study to see if changes in practice had impacted these outcomes. <h3>Methods</h3> An institutional database of patients referred to the Leonard Jones Intestinal Failure Unit at St Marks Hospital was interrogated for patients who started HPN between 1/1/04-1/10/15 and had the primary cause of their intestinal failure recorded as ‘dysmotility’ or ‘other’. The discharge and outpatient letters of those patients were inspected. Patients were excluded if there was any mechanical obstruction, IBD or coeliac disease prior to starting HPN or insufficient clinical information to rule these out. Measured outcomes were survival, intestinal transplant and independence from HPN. <h3>Results</h3> 159 patients were identified as potentially having dysmotility. 91 were excluded because dysmotility was not the primary cause of the intestinal failure or there was insufficient information, leaving 68 for the final analysis. The median age of this cohort was 39 years (range 16–78) and 19% were male. In total there were 471.2 years of follow up since starting HPN (median 4.4 (range 0.03–26.9)). 21 patients (31%) had a bowel resection before starting HPN. Overall survival 91%, (n = 62, 5 died on HPN, 1 off HPN), intestinal transplant 4% (n = 3, all successful), 29% (n = 17) were independent of HPN. 5 year outcomes were available for 18 patients. Survival at 5 years was 84% and independence from HPN was 40%. There were no transplants in this group. 23 patients had a diagnosis of chronic intestinal pseudo-obstruction (CIPO), 18 primary and 5 secondary, median follow up was 4.2 years. Overall survival was 91% and independence from HPN was 40%. 4 had positive histological diagnosis of neuropathy and 4 of myopathy. Both secondary CIPO (n = 5) and neuropathic bowel (n = 4) were predictive of independence from HPN compared to other dysmotility diagnoses, secondary CIPO odds ratio 0.03 (95%CI 0.0015–0.6, p &lt; 0.05), neuropathy odds ratio 0.098 (95%CI 0.009–1.0, p = 0.05). <h3>Conclusion</h3> Our recent data implies improved outcomes on HPN for patients with dysmotility, particularly patients with secondary CIPO. This may be due to advances in treatment of underlying conditions. <h3>Reference</h3> 1 Lloyd DA, Vega R, Bassett P, Forbes A, Gabe SM. Survival and dependence on home parenteral nutrition: experience over a 25-year period in a UK referral centre. <i>Alimentary Pharmacol Ther</i> 2006;<b>24</b>:1231–40 <h3>Disclosure of Interest</h3> None Declared
Preclinical Determination of the Efficacy of Epigenetic Therapy in High Risk Myeloid Disease Using the Zebrafish Model
Authors: Adam Deveau, Alexander Michael Forrester, Andrew J Coombs, Gretchen S Wagner, Clemens Grabher, Ian Chute, Daniel Leger, Stephen Lewis, Matthew Mingay, Martin Hirst, A. Thomas Look, Jason N. Berman
Journal: Blood (2014)
FRI0187 A Randomized Crossover Comparison of Injection Site Pain with 40 Mg/0.8 Ml and 40 mg/0.4 ml Formulations of Adalimumab in Patients with Rheumatoid Arthritis
Authors: P. Nash, J. Vanhoof, S. Hall, R. Tarzynski-Potempa, K. Unnebrink, A. Cividino
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> A new 40 mg/0.4 mL formulation of adalimumab was developed that has fewer excipients, a smaller volume, and a delivery presentation with a smaller gauge needle than the current 40 mg/0.8 mL formulation. <h3>Objectives</h3> Evaluate injection site–related pain, safety, and tolerability of the new and current formulations of adalimumab in patients with rheumatoid arthritis (RA). <h3>Methods</h3> In 2 identically designed, phase 2, randomized, single-blind, 2-period crossover studies, adults with RA (biologic-naive or current users of 40 mg/0.8 mL adalimumab with an average injection site–related pain rating ≥3 cm on a visual analog scale [VAS; 0–10 cm]) were randomized to receive 40 mg/0.8 mL or 40 mg/0.4 mL adalimumab at visit 1; after 1–2 weeks (depending on patient medication schedule), patients received the other formulation at visit 2. A pain VAS (McGill Pain Questionnaire [MPQ-SF]) and the Draize scale were evaluated immediately after injection and 15 minutes postinjection; the primary endpoint was immediate pain after injection. <h3>Results</h3> Sixty-four and 61 patients were randomized in Studies 1 and 2, respectively. Both studies found significantly lower immediate pain after injection for the 40 mg/0.4 mL versus the 40 mg/0.8 mL formulation (Table). The mean difference on the VAS for the pooled data (−2.48 cm) was statistically significant (<i>P</i>&lt;0.001) and clinically relevant; the median percent reduction was –84%. Most other endpoints in both studies favored the 40 mg/0.4 mL formulation (Table), and its tolerability and safety profiles were consistent with 40 mg/0.8 mL adalimumab (data not shown). <h3>Conclusions</h3> A 40 mg/0.4 mL adalimumab formulation was well tolerated and associated with less injection site–related pain than the 40 mg/0.8 mL adalimumab formulation. <h3>Acknowledgement</h3> AbbVie funded the study; contributed to its design; and was involved in collection, analysis, and interpretation of the data and in writing, review, and approval of the abstract. All authors contributed to and maintained control over final content. Katie Groschwitz, PhD, of Complete Publication Solutions, LLC, provided medical writing support. The authors would like to thank Monika Höbel and Hui Ding, employees of AbbVie, for statistical programming support. <h3>Disclosure of Interest</h3> P. Nash Grant/research support from: AbbVie, Speakers bureau: AbbVie, J. Vanhoof Grant/research support from: AbbVie, Pfizer, and Roche, S. Hall: None declared, R. Tarzynski-Potempa Employee of: AbbVie, K. Unnebrink Employee of: AbbVie, A. Cividino Grant/research support from: AbbVie, Pfizer, Celgene, Takeda, Roche and UCB; support for the AbbVie Chair in Education in Rheumatology
AB0462 The Risk of Cancer in Systemic Lupus Erythematosus in Chinese Population: A Single-Center Experience
Authors: J. Qi, P. Zhang, Z. Hu, Z. Chen, J. Gu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> It was reported that incidence rate of malignant tumor in general population was 0.24% in China in 2010. Cyclophosphamide is widely used in the treatment of systemic lupus erythematosus. Long term use of CTX may lead to increase the risk of tumor. However, whether the Cyclophosphamide risk of cancer will increase is not clear. <h3>Objectives</h3> To investigate the risk of cancer in systemic lupus erythematosus patients. <h3>Methods</h3> We studied retrospectively systemic lupus erythematosus patients coexist with malignancies hospitalized in the Third Affiliated hospital of Sun Yat-sen University from 1999 to 2015. The study included 2530 systemic lupus erythematosus patients. <h3>Results</h3> The ratio of systemic lupus erythematosus with malignancies was 0.24% in these patients (6/2530). Compared to general population, no increase in tumor incidence was found in systemic lupus erythematosus. The onset age of SLE was 47±17.8years,and the age of the patients with cancer were 50.7±14.9years.There were 6 solid tumor in our study, including three thyroid carcinoma, one nasopharyngeal carcinoma, one nerve glioma, and one meningioma. <h3>Conclusions</h3> The incidence of tumor in SLE patients was similar to the general populations. <h3>References</h3> Chen, W.; Zheng, R.; Zhang, S.; Zhao, P.; Zeng, H.; Zou, X., Report of cancer incidence and mortality in China, 2010. Annals of translational medicine 2014, 2 (7), 61. <h3>Disclosure of Interest</h3> None declared
The Ligand Occupancy of Endothelial Protein C Receptor Switches the PAR-1 Dependent Signaling Specificity of Thrombin from a Disruptive to a Protective Response in Endothelial Cells.
Authors: Alireza R. Rezaie, Jong-Sup Bae, Likui Yang, Chandrashekhara Manithody
Journal: Blood (2007)
Lenalidomide Oral Monotherapy Produces a 53% Response Rate in Patients with Relapsed/Refractory Mantle-Cell Non-Hodgkin’s Lymphoma.
Authors: Joseph M. Tuscano, Izidore S. Lossos, Glen Justice, Julie M. Vose, Kenichi Takeshita, Annette Ervin-Haynes, Dennis Pietronigro, Jerome B. Zeldis, Thomas M. Habermann
Journal: Blood (2007)
Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia.
Authors: Michael Y. Shapira, Tsirigotis D. Panagiotis, Reuven Or, Igor B. Resnick, Benjamin Gesundheit, Shimon Slavin
Journal: Blood (2006)
Mobilization, Harvesting and Selection of Peripheral Blood Stem Cells in Patients with Autoimmune Diseases Undergoing Non-Myeloablative Autologous Hematopoietic Stem Cell Transplantation.
Authors: Laisvyde Statkute, Larissa Verda, Yu Oyama, Marcelo Villa, Thomas Shook, Ronnie Clifton, Nela Krosnjar, Kathleen Quigley, Kimberly Yaung, Catherine Weppner, Richard K. Burt
Journal: Blood (2005)